Free Trial
NASDAQ:PHAS

PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
848,888 shs
Market Capitalization
$3.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PHAS stock logo

About PhaseBio Pharmaceuticals Stock (NASDAQ:PHAS)

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

PHAS Stock News Headlines

Alcami Announces CEO Transition
Human testing is the last step before this company goes big
Biotech innovations have the potential to change the world. And help you build wealth in the process.
8-K: PhaseBio Pharmaceuticals Inc
Human testing is the last step before this company goes big
Biotech innovations have the potential to change the world. And help you build wealth in the process.
See More Headlines
Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
7/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PHAS
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

Net Income
$-131,070,000.00
Net Margins
-12,572.13%
Pretax Margin
-12,572.13%

Debt

Sales & Book Value

Annual Sales
$818,000.00
Book Value
($1.93) per share

Miscellaneous

Free Float
44,922,000
Market Cap
$3.50 million
Optionable
Not Optionable
Beta
2.57
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

Key Executives

  • Jonathan P. Mow
    Chief Executive Officer & Director
  • John P. Sharp
    Chief Financial Officer
  • John S. Lee
    Chief Medical Officer
  • Kristopher L. Hanson
    Secretary, Senior VP & General Counsel
  • Susan E. Arnold
    Senior Vice President-Technical Operations

PHAS Stock Analysis - Frequently Asked Questions

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.07. The company earned $0.34 million during the quarter, compared to analyst estimates of $2.67 million.

When did PhaseBio Pharmaceuticals IPO?

PhaseBio Pharmaceuticals (PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel served as the underwriters for the IPO and Needham was co-manager.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB) and Sorrento Therapeutics (SRNE).

This page (NASDAQ:PHAS) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners